Pulmonary diseases associated with inflammatory bowel diseases

Casella, Giovanni; Villanacci, Vincenzo; Bella, Camillo Di; Antonelli, Elisabetta; Baldini, Vittorio; Bassotti, Gabrio

doi:10.1016/j.crohns.2010.02.005

Cited by 40 publications

(30 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the present case, an infectious cause of bronchitis was excluded based on the findings of repeated sputum and blood cultures with no evidence of infection. Mesalazine, the principal drug for IBD treatment, is also responsible for respiratory complications, such as interstitial disease and eosinophilic pleuritis or pneumonia (18). However, the present patient's respiratory symptoms remitted without interruption of this drug.…”

Section: Discussionmentioning

confidence: 58%

Tracheobronchitis with Dyspnea in a Patient with Ulcerative Colitis

et al. 2015

View full text Add to dashboard Cite

We herein report the case of a 42-year-old man with a one-year history of ulcerative colitis who presented with exacerbated bloody diarrhea, a productive cough and increasing breathing difficulties. Colonoscopy revealed typical deep ulcers in the rectosigmoid colon and atypical multiple sucker-like ulcers in the transverse colon, and computed tomography of the chest demonstrated wall thickening of the trachea and bronchi. In addition, bronchoscopy showed ulcers in the trachea, and histopathology disclosed findings of necrosis and inflammation of the subepithelial tissue of the trachea. Based on these findings, the patient's respiratory symptoms were strongly suspected to be due to ulcerative colitis-related tracheobronchitis. Treatment with systemic corticosteroids subsequently resulted in a rapid clinical improvement.

show abstract

Section: Discussionmentioning

confidence: 58%

Tracheobronchitis with Dyspnea in a Patient with Ulcerative Colitis

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Additionally, the drugs used to treat IBD, such as mesalazine, sulfasalazine, and azathioprine, can cause pleuropericarditis (4). Of the 18 cases of mesalazine-induced intrathoracic lesions (e.g., pleuropericarditis, pericarditis, myopericarditis, and pleuritis) that were identified by searching the PubMed database (Table) (1, 2, 5-19), only two cases experienced mesalazineinduced pericarditis with CD.…”

Section: Discussionmentioning

confidence: 99%

Mesalazine-induced Pleuropericarditis in a Patient with Crohn's Disease

et al. 2015

View full text Add to dashboard Cite

A 16-year-old boy was diagnosed with Crohn's disease. Treatment with oral mesalazine was started at 3 g per day; however, he complained of high fever, a nonproductive cough, and left shoulder pain after 2 weeks. His chest radiography and chest computed tomography showed cardiomegaly and left pleural effusion, while an echocardiogram revealed pericardial effusion. Because no infection was detected by thoracentesis and the drug lymphocyte stimulation tests for mesalazine were positive, the patient was diagnosed with mesalazineinduced pleuropericarditis. After the cessation of mesalazine, the clinical symptoms and laboratory findings quickly improved.

show abstract

“…A broad spectrum of pulmonary involvement (mainly interstitial) has been described in association with such treatments. 6 In this situation, it is important to distinguish between pulmonary involvement as an extra-intestinal manifestation of IBD and drug-induced pulmonary complications. Bronchoalveolar lavage characteristics can be helpful in differentiation, with a lymphocytic bronchoalveolar lavage found in Crohn's disease-related interstitial lung diseases versus an eosinophilic bronchoalveolar lavage in drug-induced pulmonary interstitial complications.…”

Section: Discussionmentioning

confidence: 99%

“…5 The pathogenesis of lung involvement associated with IBD is uncertain, but the common embryologic origin of the lungs and gastrointestinal tract may theoretically play a role through shared antigenicity. 5,6 Pulmonary involvement in IBD can represent a diagnostic challenge especially if it occurs in a patient who is maintained on steroid-sparing agents for IBD, such as sulfasalazine, mesalamine, azathioprine, 6-mercaptopurine, methotrexate, or biologic therapeutic agents. A broad spectrum of pulmonary involvement (mainly interstitial) has been described in association with such treatments.…”

Section: Discussionmentioning

confidence: 99%

Pulmonary Necrobiotic Nodules in Crohn's Disease: A Rare Extra-intestinal Manifestation

El‐Kersh¹,

Fraig

Cavallazzi³

et al. 2014

Respir Care

View full text Add to dashboard Cite

Pulmonary necrobiotic nodules represent a rare extra-intestinal manifestation of Crohn's disease. Histologically, they are composed of sterile aggregates of inflammatory cells with necrosis. The differential diagnosis is broad, and exclusion of infectious etiologies is mandatory before starting immunosuppressive therapy. Here, we present the fifth reported case of pulmonary necrobiotic nodules in Crohn's disease. Our patient had new-onset Crohn's disease associated with both cavitating and non-cavitating lung nodules that were confirmed to be necrobiotic nodules by biopsy. The patient was started on mesalamine and prednisone, with subsequent improvement of his gastrointestinal symptoms and regression of the necrobiotic nodules. Key words: pulmonary necrobiotic nodules; Crohn's disease; video-assisted thoracoscopy. [Respir Care 2014;59(12):e190 -e192.

show abstract

Pulmonary diseases associated with inflammatory bowel diseases

Cited by 40 publications

References 75 publications

Tracheobronchitis with Dyspnea in a Patient with Ulcerative Colitis

Tracheobronchitis with Dyspnea in a Patient with Ulcerative Colitis

Mesalazine-induced Pleuropericarditis in a Patient with Crohn's Disease

Pulmonary Necrobiotic Nodules in Crohn's Disease: A Rare Extra-intestinal Manifestation

Contact Info

Product

Resources

About